{"disease":{"id":"node-negative-breast-cancer","name":"node negative breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02927249","title":"Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3021,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03413761","title":"Antioxidant Supplements, Genetics and Chemotherapy Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1771,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT04569747","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":393,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04675827","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":139,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT05150652","title":"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Irada Ibrahim-zada","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}